This morning, the long-rumored merger between Takeda Pharmaceutical Company Ltd (TPKYY) and Shire plc (SHPG) has been approved by both companies boards for the consideration of $30.33 in cash and either .839 shares stock or 1.679 ADS for each Shire share. (Takeda’s current NYSE listing is at a 2:1 ratio, hence the differential). Shire shareholders will also be entitled to dividends paid or declared through the merger effective date.
The combination is expected to complete in the first half of 2019 and will result (I believe) in the eighth largest pharma company. Takeda expects to maintain both its’ dividend policy and investment grade rating.
My investment came about via Baxter’s spin of Baxalta which was subsequently acquired by Shire. The overall investment is currently a little under water but the cash portion of this deal should mitigate this to a degree. Apparently a major concern is that some large holders don’t care to hold Japanese paper. Although Japan’s monetary policy (and resulting exchange rate) is a potential issue, my belief is that the combined company will have enough of a worldwide footprint to offset this.
Therefore I favor this deal and expect to increase my Shire holdings enough to avoid a weird fractional allocation of shares based on the merger terms.